NervGen Pharma to Voluntarily Delist from TSX Venture Exchange, Consolidating Trading on Nasdaq

summarizeSummary

NervGen Pharma Corp. will voluntarily delist its common shares from the TSX Venture Exchange to streamline operations and reduce costs, with trading continuing on the Nasdaq Capital Market.

check_boxKey Events

• Voluntary Delisting from TSX Venture Exchange

  NervGen Pharma Corp. will voluntarily delist its common shares from the TSX Venture Exchange, effective March 16, 2026, to reduce costs and administrative burden.

• Continued Trading on Nasdaq Capital Market

  The company's common shares will continue to trade on the Nasdaq Capital Market under the symbol "NGEN", ensuring ongoing liquidity for shareholders.

• Strategic Rationale for Delisting

  The decision aligns with the company's evolution into late-stage development for NVG-291, aiming to eliminate duplicative fees and reduce regulatory complexity.

• Termination of ATM Program

  In connection with the delisting, the company terminated its at-the-market equity program, under which it had issued 245 common shares for aggregate net proceeds of $1,489 since January 1, 2026.

auto_awesomeAnalysis

NervGen Pharma Corp. announced its voluntary delisting from the TSX Venture Exchange, effective March 16, 2026. This strategic move aims to reduce duplicative exchange fees, legal, accounting, and regulatory complexities, allowing management to focus more on clinical execution and shareholder value. While the delisting removes a trading venue, the company's common shares will continue to trade on the Nasdaq Capital Market, ensuring uninterrupted liquidity for all shareholders. This decision, made while the stock is trading near its 52-week low, suggests a focus on operational efficiency and cost savings to extend the company's runway as it advances its lead drug candidate, NVG-291, into late-stage development. Concurrently, the company terminated its previously announced at-the-market equity program, which had seen minimal activity.